Effects of IL-4 and RANKL synergism on survival of peripheral blood monocytes in patients with giant cell granuloma

References

• 1.
  Spraggs P, Roth J, Young-Ramsaran J, Goodwin WJ. Giant cell reparative granuloma of the maxilla.Ear Nose Throat J 1997; 76:445-446, 449.
• 2.
  Tsichlaki A, George KS, Manisali M. An unusual presentation of a maxillary central giant cell granuloma.J Surg Case Rep 2012; 2012:7.
• 3.
  Pogrel AM. The diagnosis and management of giant cell lesions of the jaws.Ann MaxillofacSurg2012; 2:102-106.
• 4.
  Vignery A. Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int J ExpPathol2000; 81:291-304.
• 5.
  Khoramian S, Poureslami H, Mohammadi B. Central giant cell granuloma: (A Case Report). J RafsanjanUniv Med Sci 2012; 11:503-510. (Persian).
• 6.
  Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol2005;5:953-964.
• 7.
  Pak F, Barati M, Shokrolahi M, Kokhaei P. Tumor immunology and tumor escape mechanisms from immune response. Koomesh 2014; 15:412-430. (Persian).
• 8.
  Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29:403-440.
• 9.
  Moreno JL, Mikhailenko I, Tondravi MM, Keegan AD. IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin. J LeukocBiol 2007; 82:1542-1553.
• 10.
  Yu M, Qi X, Moreno JL, Farber DL, Keegan AD. NF-kappaB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-kappaB pathways. J Immunol 2011; 187:1797-1806.
• 11.
  Mirmohammadkhani O, Motahari P, Ghanadan A, Chahardehi R, Mirmohammadkhani M. Activated leukocyte cell adhesion molecule expression in oral squamus cell carcinoma and its association with clinical and histopathologic parameters. Koomesh 2013; 14:350-356.
• 12.
  Moreno JL, Kaczmarek M, Keegan AD, Tondravi M. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. Blood 2003; 102:1078-1086.
• 13.
  Breuil V, Schmid-Antomarchi H, Schmid-Alliana A, Rezzonico R, Euller-Ziegler L, Rossi B. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003; 17:1751-1753.
• 14.
  Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev2006;210:171-186.
• 15.
  Aghbali A, Rafieyan S, Mohamed-Khosroshahi L, Baradaran B, Shanehbandi D, Kouhsoltani M. IL-4 induces the formation of multinucleated giant cells and expression of beta5 integrin in central giant cell lesion. Med Oral Patol Oral Cir Bucal 2017; 22:e1-e6.
• 16.
  Regezi JA. Comments on the pathogenesis and medical treatment of central giant cell granulomas.J Oral MaxillofacSurg 2004;62:116-118.
• 17.
  Kruse-Lsler B, Diallo R, Gaertner C, Mischke KL, Joos U, Kleinheinz J. Central giant cell granuloma of the jaws: a clinical, radiologic, and histopathologic study of 26 cases. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 2006; 101:346-354.
• 18.
  Eckardt A, Pogrel MA, Kaban LB, Chew K, Mayall BH. Central giant cell granulomas of the jaws: nuclear DNA analysis using image cytometry. Int J Oral MaxillofacSurg 1989; 18:3-6.
• 19.
  Whitaker SB, Waldron CA. Central giant cell lesions of the jaws: a clinical, radiologic, and histopathologic study. Oral Surg Oral Med Oral Pathol 1993; 75:199-208.
• 20.
  Lim L, Gibbins JR. Immunohistochemical and ultrastructural evidence of a modified microvasculature in the giant cell granuloma of the jaws. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 1995; 79:190-198.
• 21.
  Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-B in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000; 156:761-767. ##.